10:31 AM EST - OpSens Inc. : Reported its results for the first quarter of fiscal year 2023 ended November 30, 2022. First Quarter Fiscal 2023 Financial Highlights. Consolidated revenues of $10.2 million, compared with $8.1 million, a 26% increase and a new quarterly record; Increased gross margin to 58% in the first quarter of 2023 compared with 51%; Coronary artery disease sales of $5.2 million in the first quarter of 2023 compared with $4.9 million, a 6% increase; TAVR sales of $0.4 million in the first quarter of 2023. Sales of optical medical products, including the supply agreement with Abiomed, were $3.3 million in the first quarter of 2023, an increase of 38%, compared with $2.4 million; Cash and cash equivalents of $17.5 million at November 30, 2022 ($23.8 million at August 31, 2022). OpSens Inc.
shares T.OPS are trading up $0.15 at $1.90.
